BRISBANE, Australia and MINNEAPOLIS, USA,
Anteris Technologies Ltd (Anteris or the Company) (ASX: AVR) is pleased to announce that the United States Patent and Trademark Office has issued a utility patent to the Company for the novel DurAVR™ transcatheter heart valve (THV).
DurAVR™ THV is a first-in-class biomimetic valve uniquely designed to mimic the performance of a healthy human heart valve. The patent number 11,622,853, which expires 30 September 2042, further confirms that the Company has developed a differentiated heart valve technology through its innovative single-piece, shaped-tissue design.
The Company believes the unique aspects of the DurAVR™ design, including the single-piece valve construction, account for the excellent clinical results to date. “The patent signifies the extraordinary work by our team of engineers around the world responsible for the design of DurAVR™ THV.
The granting of this patent enhances the broad IP protection of DurAVRTM, strengthening our competitive position in the TAVR field,” said Wayne Paterson, CEO.
...well done team ....
AVR Price at posting:
$22.50 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)